BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 19088696)

  • 1. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
    Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term prognosis of medullary thyroid carcinoma.
    Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Medullary carcinoma of the thyroid: diagnosis and therapy].
    Giuffrida D; Ferraù F; Bordonaro R; Mattina M; Priolo D; Aiello RA; Cordio S; Motta S; Failla G
    Clin Ter; 2000; 151(1):29-35. PubMed ID: 10822879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
    Łacka K; Michałek K; Majewski P
    Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
    Quayle FJ; Moley JF
    J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
    Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
    Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma.
    Hoefnagel CA; Delprat CC; Valdés Olmos RA
    J Nucl Biol Med (1991); 1991; 35(4):334-6. PubMed ID: 1823851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.
    Rufini V; Castaldi P; Treglia G; Perotti G; Gross MD; Al-Nahhas A; Rubello D
    Biomed Pharmacother; 2008 Mar; 62(3):139-46. PubMed ID: 17892924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medullary thyroid carcinoma: state of the art.
    Favia G; Iacobone M
    G Chir; 2005; 26(11-12):405-9. PubMed ID: 16472416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.
    Kraeber-Bodéré F; Salaun PY; Oudoux A; Goldenberg DM; Chatal JF; Barbet J
    Cancer; 2010 Feb; 116(4 Suppl):1118-25. PubMed ID: 20127952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medullary thyroid carcinoma: surgical treatment advances.
    Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 131I-MIBG therapy of neural crest tumours (review).
    Troncone L; Rufini V
    Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medullary thyroid carcinoma.
    Leboulleux S; Baudin E; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and therapeutic aspects in medullary thyroid carcinoma.
    Safioleas M; Stamatakos M; Karampali E; Rompoti N; Mouzopoulos G; Lygidakis N
    Chirurgia (Bucur); 2006; 101(2):121-6. PubMed ID: 16752676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature.
    Bhanot P; Yang J; Schnadig VJ; Logroño R
    Diagn Cytopathol; 2007 May; 35(5):285-92. PubMed ID: 17427218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medullary thyroid carcinoma and some of its particularities].
    Sidibé el H
    Sante; 2007; 17(1):51-5. PubMed ID: 17897902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of metastases from medullary thyroid carcinoma using different methods.
    Cabezas RC; Berna L; Estorch M; Carrio I; Garcia-Ameijeiras A
    Henry Ford Hosp Med J; 1989; 37(3-4):169-72. PubMed ID: 2639132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
    Vainas I; Koussis Ch; Pazaitou-Panayiotou K; Drimonitis A; Chrisoulidou A; Iakovou I; Boudina M; Kaprara A; Maladaki A
    J Exp Clin Cancer Res; 2004 Dec; 23(4):549-59. PubMed ID: 15743023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.